Copy to clipboard 
ORTHOWORLD estimates Stryker’s 4Q17 orthopaedic revenue at US $1,816.8MM, +7.7% from 4Q16, and 2017 revenue of $6,670.1MM, +5.4% vs. 2016. Estimated segment sales and growth follow.
| 4Q17 | 4Q16 | $ Change | % Change | |
| Joint Reconstruction | $986.6 | $915.5 | $71.1 | 7.8% |
| Knee | $562.0 | $513.4 | $48.6 | 9.5% |
| Hip | $394.2 | $374.7 | $19.6 | 5.2% |
| Extremities | $30.4 | $27.4 | $3.0 | 10.8% |
| Trauma | $380.3 | $340.3 | $40.0 | 11.7% |
| Arthroscopy/Soft Tissue | $130.8 | $123.0 | $7.8 | 6.3% |
| Spine | $187.0 | $183.8 | $3.2 | 1.7% |
| Orthobiologics | $59.9 | $55.9 | $4.0 | 7.2% |
| Other* | $69.8 | $68.0 | $1.8 | 2.6% |
| Total | $1,814.3 | $1,686.5 | $127.9 | 7.6% |
| 2017 | 2016 | $ Change | % Change | |
| Joint Reconstruction | $3,584.5 | $3,408.0 | $176.5 | 5.2% |
| Knee | $2,011.5 | $1,870.9 | $140.6 | 7.5% |
| Hip | $1,457.9 | $1,432.9 | $25.0 | 1.7% |
| Extremities | $115.1 | $104.2 | $10.9 | 10.4% |
| Trauma | $1,378.1 | $1,265.8 | $112.3 | 8.9% |
| Arthroscopy/Soft Tissue | $494.0 | $461.5 | $32.5 | 7.0% |
| Spine | $707.1 | $712.5 | -$5.3 | -0.8% |
| Orthobiologics | $219.4 | $207.7 | $11.7 | 5.7% |
| Other* | $286.9 | $275.4 | $11.6 | 4.2% |
| Total | $6,670.1 | $6,330.8 | $339.3 | 5.4% |
*Includes CMF, Performance Solutions
Mako momentum continues. In 4Q, SYK made 35 Mako robot installations globally, with 27 in the U.S., and logged the first robot sale in Japan where approval for the total knee application is expected by the end of 2018. Unit sales continue their sequential rise, up from 33 sold in 3Q.
Since the total knee launched in 1Q17, >800 surgeons have received training—200 in 4Q. In 2017, 15,778 total knee procedures were performed, with 20% used by competitive surgeons using the Triathlon total knee for the first time. Of the full-year number of procedures, 7,000 occurred in 4Q, up from 4,500 in 3Q.
After the 4Q receipt of FDA 510(k) clearance to market Mako with Triathlon cementless components, SYK ended the year with 24% of its knee procedures done without cement.
Procedures for all Mako applications—total and partial knees plus hips—grew by 93% over 2016, reaching 42,500, with all three applications growing (though individual growth rates aren’t stated). Trident 2, the 3D-printed acetabular cup, is now moving into full launch, which may give a boost to Mako in hips.
Mako aside, other growth contributors included strong demand for 3D-printed products, the foot/ankle portfolio, shoulders and, in the U.S., interventional spine.
Within 2017, the company’s foot/ankle division launched Hoffmann LRF Hexapod hardware and a pre-and post-op planning tool for deformity correction and limb reconstruction. Surgeons can upload a patient’s x-ray into the software, which calculates a treatment solution based on the surgeon’s manual input and then creates a patient-specific plan for strut adjustments.
New product launches in spine should help boost performance in that segment. Stryker Spine announced FDA 510(k) clearance to market the Serrato™ Pedicle Screw in August, and by the end of September, >100 were implanted by U.S. surgeons. The Tritanium C Anterior Cervical Cage, launched in October, adds to the company’s line of highly-porous devices enabled by the AMagine™ additive manufacturing approach. Finally, Vexim’s SpineJack system may gain FDA 510(k) clearance in 2018, bolstering interventional spine following SYK’s acquisition of Vexim at the close of 2017.
Sources: Stryker Corp.; ORTHOWORLD estimates
ORTHOWORLD estimates Stryker’s 4Q17 orthopaedic revenue at US $1,816.8MM, +7.7% from 4Q16, and 2017 revenue of $6,670.1MM, +5.4% vs. 2016. Estimated segment sales and growth follow.
Q17
Q16
$ Change
% Change
Joint...
ORTHOWORLD estimates Stryker’s 4Q17 orthopaedic revenue at US $1,816.8MM, +7.7% from 4Q16, and 2017 revenue of $6,670.1MM, +5.4% vs. 2016. Estimated segment sales and growth follow.
| 4Q17 | 4Q16 | $ Change | % Change | |
| Joint Reconstruction | $986.6 | $915.5 | $71.1 | 7.8% |
| Knee | $562.0 | $513.4 | $48.6 | 9.5% |
| Hip | $394.2 | $374.7 | $19.6 | 5.2% |
| Extremities | $30.4 | $27.4 | $3.0 | 10.8% |
| Trauma | $380.3 | $340.3 | $40.0 | 11.7% |
| Arthroscopy/Soft Tissue | $130.8 | $123.0 | $7.8 | 6.3% |
| Spine | $187.0 | $183.8 | $3.2 | 1.7% |
| Orthobiologics | $59.9 | $55.9 | $4.0 | 7.2% |
| Other* | $69.8 | $68.0 | $1.8 | 2.6% |
| Total | $1,814.3 | $1,686.5 | $127.9 | 7.6% |
| 2017 | 2016 | $ Change | % Change | |
| Joint Reconstruction | $3,584.5 | $3,408.0 | $176.5 | 5.2% |
| Knee | $2,011.5 | $1,870.9 | $140.6 | 7.5% |
| Hip | $1,457.9 | $1,432.9 | $25.0 | 1.7% |
| Extremities | $115.1 | $104.2 | $10.9 | 10.4% |
| Trauma | $1,378.1 | $1,265.8 | $112.3 | 8.9% |
| Arthroscopy/Soft Tissue | $494.0 | $461.5 | $32.5 | 7.0% |
| Spine | $707.1 | $712.5 | -$5.3 | -0.8% |
| Orthobiologics | $219.4 | $207.7 | $11.7 | 5.7% |
| Other* | $286.9 | $275.4 | $11.6 | 4.2% |
| Total | $6,670.1 | $6,330.8 | $339.3 | 5.4% |
*Includes CMF, Performance Solutions
Mako momentum continues. In 4Q, SYK made 35 Mako robot installations globally, with 27 in the U.S., and logged the first robot sale in Japan where approval for the total knee application is expected by the end of 2018. Unit sales continue their sequential rise, up from 33 sold in 3Q.
Since the total knee launched in 1Q17, >800 surgeons have received training—200 in 4Q. In 2017, 15,778 total knee procedures were performed, with 20% used by competitive surgeons using the Triathlon total knee for the first time. Of the full-year number of procedures, 7,000 occurred in 4Q, up from 4,500 in 3Q.
After the 4Q receipt of FDA 510(k) clearance to market Mako with Triathlon cementless components, SYK ended the year with 24% of its knee procedures done without cement.
Procedures for all Mako applications—total and partial knees plus hips—grew by 93% over 2016, reaching 42,500, with all three applications growing (though individual growth rates aren’t stated). Trident 2, the 3D-printed acetabular cup, is now moving into full launch, which may give a boost to Mako in hips.
Mako aside, other growth contributors included strong demand for 3D-printed products, the foot/ankle portfolio, shoulders and, in the U.S., interventional spine.
Within 2017, the company’s foot/ankle division launched Hoffmann LRF Hexapod hardware and a pre-and post-op planning tool for deformity correction and limb reconstruction. Surgeons can upload a patient’s x-ray into the software, which calculates a treatment solution based on the surgeon’s manual input and then creates a patient-specific plan for strut adjustments.
New product launches in spine should help boost performance in that segment. Stryker Spine announced FDA 510(k) clearance to market the Serrato™ Pedicle Screw in August, and by the end of September, >100 were implanted by U.S. surgeons. The Tritanium C Anterior Cervical Cage, launched in October, adds to the company’s line of highly-porous devices enabled by the AMagine™ additive manufacturing approach. Finally, Vexim’s SpineJack system may gain FDA 510(k) clearance in 2018, bolstering interventional spine following SYK’s acquisition of Vexim at the close of 2017.
Sources: Stryker Corp.; ORTHOWORLD estimates
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
